Pulse Biosciences (PLSE) Announces Preliminary Results for its Rights Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
June 28, 2024 8:00 AM EDTOversubscribed offering expected to generate $60 million in immediate gross proceeds for the Company
Warrants issued in the offering could generate up to an additional $66MM
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation (nsPFA) technology, announced today the preliminary results of its rights offering, which expired at 5:00 p.m., Eastern Time, on June 26, 2024 (the Expiration Date).
In accordance with the pricing structure described in the prospectus supplement... More
